查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941869

笔式和注射器式给药装置市场规模、份额和趋势分析报告：按产品、治疗应用、最终用途、地区和细分市场预测（2026-2033 年）

Pen And Injector Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product (Injectors, Pen), By Therapeutic Use (Autoimmune Disorders, Hormonal Disorders), By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

笔式和注射器式给药装置市场概述

2025年全球笔式和注射器式给药装置的市场规模估计为1,146.7亿美元，预计到2033年将达到2,365.4亿美元。

我们预计从 2026 年到 2033 年，年复合成长率将达到 9.6%。这一强劲成长是由医疗保健领域对先进、有效和用户友好的药物传输解决方案的需求不断增长所驱动的。

关键驱动因素包括：需要频繁注射的慢性疾病（如糖尿病、癌症和自体免疫疾病）盛行率不断上升；便捷易用的注射工具（如自动注射器和笔式註射器）的广泛应用；以及不断提升安全性、准确性和患者舒适度的技术进步。此外，生物製药研发的拓展、居家医疗的兴起以及减少住院次数的日益重视也进一步推动了市场成长。

笔式和注射器式给药装置市场的主要驱动因素之一是慢性病盛行率的上升和老年人口的快速成长。糖尿病、癌症、心血管疾病和自体免疫疾病等慢性病通常需要定期或长期注射给药，才能达到快速有效的治疗效果。根据国际糖尿病联盟（IDF）2021年的报告，全球约有5.37亿人患有糖尿病，这意味着大约十分之一的人口受到影响。预计到2045年，这一数字将达到7.83亿，并且预计成长速度将很快。随着这些疾病在全球范围内的增加，对可靠且易于使用的注射器装置的需求持续增长。此外，老化社会往往面临多种健康问题，并且往往需要频繁的医疗程序，包括注射药物。根据联合国经济和社会事务部人口司的最新估计和预测，到2050年，60岁及以上人口预计将达到15亿，约占世界人口的六分之一。人口结构的变化推动了对方便、安全、精确的管理系统的需求，这些系统既支持临床环境也支持居家照护，从而显着促进了市场成长。

药物输送系统的技术进步推动了笔式和注射器式药物输送装置的成长。创新让注射装置更安全、更有效率，也更方便病人使用。智慧型自动注射器配备数位监控功能、无针注射技术以及改进的安全机制等特性，有助于确保剂量精准，并降低针刺伤的风险。材料和装置设计的进步也提高了舒适度，并支持患者在家中自行使用，这对慢性病管理者日益重要。例如，2024年10月，BD和Ypsomed宣布建立策略伙伴关係，将BD的「Neopak XtraFlow」玻璃预填充式注射器（配备8毫米短针头和薄壁套管）整合到Ypsomed的「YpsoMate 2.25」自动注射器中。这种设计使患者在家中自行注射高黏度生物製药更加便捷，而两段式註射器则专门为握力或视力受限的使用者设计。

这些技术进步将促进技术普及，并支持市场显着成长。

目录

第一章：调查方法和范围

第二章执行摘要

第三章：笔式和注射器式给药装置的市场变数、趋势、市场发展历程与展望

  • 市场动态
  • 产业分析工具
  • CDMO製造商名单以及向各公司供应的笔式和注射器式给药装置
  • 笔式和注射器式给药装置製造商名单
  • （按地区分類的）关于新型注射剂和口服药物以及高剂量装置开发的潜在影响的定性研究结果。
  • 全球CDMO笔式和注射器式给药装置市场：按产品划分，2021-2033年（以金额为准和销售）

第四章 笔式和注射器式给药装置市场：产品分析

  • 波动分析和市场份额（2025 年和 2033 年）
  • 笔式和注射器式给药装置的市场估算和预测
  • 市场规模、预测与趋势分析（2021-2033）
    • 注射器
    • 笔

第五章 笔式和注射器式给药装置市场：按治疗应用分類的估算和趋势分析

  • 波动分析和市场份额（2025 年和 2033 年）
  • 笔式和注射器式给药装置的市场估算和预测
  • 市场规模、预测与趋势分析（2021-2033）
    • 自体免疫疾病
    • 内分泌疾病
    • 肿瘤学
    • 肥胖
    • 糖尿病
    • 其他的

第六章 笔式和注射器式给药装置市场：依最终用途分析

  • 波动分析和市场份额（2025 年和 2033 年）
  • 笔式和注射器式给药装置的市场估算和预测
  • 市场规模、预测与趋势分析（2021-2033）

第七章 笔式和注射器式给药装置市场：区域估算和趋势分析

  • 笔式和注射器式给药装置市场：区域展望
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚洲
    • 中国
    • 日本
    • 印度
    • 泰国
    • 韩国
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 笔式和注射器式给药装置市场：竞争分析

  • 公司分类
  • 参与公司概况
  • 财务业绩
  • 提供的产品
  • 企业市场分析
  • 企业市场占有率分析（2024 年，%）
  • 策略规划
    • 产品上市及核准情况
    • 伙伴关係与合作
    • 併购
    • 业务拓展
    • 其他的
  • 公司简介
    • Novo Nordisk A/S
    • Sanofi
    • Eli Lilly and Company
    • AstraZeneca plc
    • Pfizer, Inc.
    • Merck KGaA
    • Teva Pharmaceuticals
    • Amgen, Inc.
    • Ferring Pharmaceuticals
    • AbbVie, Inc.
Product Code: GVR-4-68040-850-3

Pen And Injector Drug Delivery Devices Market Summary

The global pen and injector drug delivery devices market size was estimated at USD 114.67 billion in 2025 and is projected to reach USD 236.54 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This strong growth is driven by the rising demand for advanced, effective, and user-friendly drug delivery solutions across healthcare settings..

Key drivers include the increasing prevalence of chronic conditions such as diabetes, cancer, and autoimmune disorders that require frequent injections; growing adoption of user-friendly injection tools such as autoinjectors and pen injectors; and continuous technological advancements that enhance safety, accuracy, and patient comfort. In addition, growing biological development, the shift toward home-based care, and greater focus on reducing hospital visits are further supporting market growth.

One of the major drivers of the pen and injector drug delivery devices market is the increasing prevalence of chronic diseases, along with the rapid growth of the geriatric population. Chronic conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders often require regular or long-term medication delivered through injections for fast and effective therapeutic action. According to the IDF's 2021 report, about 537 million people around the world had diabetes, which means roughly 1 in 10 people were affected. The number is expected to rise sharply, reaching 783 million people by 2045. As these diseases become more common in the world, the demand for reliable and easy-to-use injectable devices continues to increase. In addition, the aging population faces multiple health issues and typically requires frequent medical treatments, including injectable drugs. According to the recent population estimates and projections by UN DESA's Population Division, the number of people aged 60 and older is projected to reach 1.5 billion by 2050, representing about 1 in 6 people globally. This demographic shift is supporting the need for convenient, safe, and precise delivery systems that support both clinical use and home-based care, thereby contributing significantly to market growth.

Technological advancements in drug delivery systems are driving the growth of pen and injector drug delivery devices. Innovations have made injection devices safer, more efficient, and easier for patients to use. Features such as smart autoinjectors with digital monitoring, needle-free injection technologies, and improved safety mechanisms help ensure accurate dosing and reduce the risk of needle injuries. Advancements in materials and device design also enhance comfort and support self-use at home, which is becoming increasingly important for people managing chronic diseases. For instance, in October 2024, BD and Ypsomed announced a strategic collaboration to integrate BD's Neopak XtraFlow glass prefillable syringe, featuring a shorter 8 mm needle and a thinner-wall cannula, with Ypsomed's YpsoMate 2.25 autoinjector. This design makes high-viscosity biologic drugs easier to inject for patients self-administering at home, and the two-step injector is purpose-built to assist users with

limited grip or vision. Such technological improvements encourage adoption and support significant market growth.

Global Pen And Injector Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pen and injector drug delivery devices market report on the basis of product, therapeutic use, end use, and region.

  • Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • Injectors
    • GLP-1 Agonists
    • Hormone Therapies
    • Biologics
    • Others
  • Pen
    • GLP-1 Agonists
    • Insulin
    • Hormone Therapies
    • Others
  • Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • Autoimmune Disorders
  • Hormonal Disorders
  • Oncology
  • Obesity
  • Diabetes Mellitus
  • Others
  • End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Homecare Settings
  • Others
  • Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Sweden
    • Denmark
  • Asia
    • China
    • Japan
    • India
    • Thailand
    • South Korea
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Drug Type
    • 1.2.3. Therapeutic Use
    • 1.2.4. End Use
  • 1.3. Estimation and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Materials & Third-Party Perspectives
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
      • 1.8.1.1. Research Scope and Assumptions
      • 1.8.1.2. Research Methodology and Assumptions
    • 1.8.2. Volume Price Analysis
    • 1.8.3. CDMO Pen and Injector Drug Delivery Devices Market
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objectives
    • 1.11.1. Objective 1
    • 1.11.2. Objective 2
    • 1.11.3. Objective 3

Chapter 2. Executive Summary

  • 2.1. Market Snapshot (Regional)
  • 2.2. Segment Snapshot (Product)
  • 2.3. Segment Snapshot (Therapeutic Use)
  • 2.4. Segment Snapshot (End Use)
  • 2.5. Market Concentration

Chapter 3. Pen and Injector Drug Delivery Devices Market Variables and Trends Market Lineage Outlook

  • 3.1. Market Dynamics
    • 3.1.1. Market Driver Impact Analysis
    • 3.1.2. Market Restraint Analysis
    • 3.1.3. Market Opportunity Analysis
  • 3.2. Industry Analysis Tools
    • 3.2.1. Porter's Five Forces Analysis
    • 3.2.2. Macroeconomic Analysis
  • 3.3. List of CDMO Manufacturers and Supplied Pen and Injector Drug Delivery Devices to Companies
  • 3.4. List of In-House Manufacturers of Pen and Injector Drug Delivery Devices
  • 3.5. Qualitative Insights on Potential Impact of New Injectables or Oral Drugs and Development of Multi-Dose Devices, by Region
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia
  • 3.6. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021-2033 (value in USD Billion and Volume in Units Sold)
    • 3.6.1. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021- 2033 (USD Billion)
    • 3.6.2. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021- 2033 (Units)

Chapter 4. Pen and Injector Drug Delivery Devices Market: Product Analysis

  • 4.1. Product Movement Analysis & Market Share, 2025 & 2033
  • 4.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Product (USD Billion, Units)
  • 4.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
    • 4.3.1. Injectors
      • 4.3.1.1. Injectors Market, 2021 - 2033 (USD Billion, Units)
      • 4.3.1.2. GLP-1 Agonists
        • 4.3.1.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
      • 4.3.1.3. Hormone Therapies
        • 4.3.1.3.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
      • 4.3.1.4. Biologics
        • 4.3.1.4.1. Biologics Market, 2021 to 2033 (USD Billion, Units)
      • 4.3.1.5. Others
        • 4.3.1.5.1. Others Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2. Pen
      • 4.3.2.1. Pens Market, 2021 - 2033 (USD Billion, Units)
      • 4.3.2.2. GLP-1 Agonists
        • 4.3.2.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
      • 4.3.2.3. Insulin
        • 4.3.2.3.1. Insulin Market, 2021 to 2033 (USD Billion, Units)
      • 4.3.2.4. Hormone Therapies
        • 4.3.2.4.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
      • 4.3.2.5. Others
        • 4.3.2.5.1. Other Market Estimates & Forecasts, 2021 to 2033 (USD Billion, Units)

Chapter 5. Pen and Injector Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis

  • 5.1. Therapeutic Area Movement Analysis & Market Share, 2025 & 2033
  • 5.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Therapeutic Use (USD Billion, Units)
  • 5.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
    • 5.3.1. Autoimmune Disorders
      • 5.3.1.1. Autoimmune Disorders Market, 2021 to 2033 (USD Billion, Units)
    • 5.3.2. Hormonal Disorders
      • 5.3.2.1. Hormonal Disorders Market, 2021 to 2033 (USD Billion, Units)
    • 5.3.3. Oncology
      • 5.3.3.1. Oncology Market, 2021 to 2033 (USD Billion, Units)
    • 5.3.4. Obesity
      • 5.3.4.1. Obesity Market, 2021 to 2033 (USD Billion, Units)
    • 5.3.5. Diabetes Mellitus
      • 5.3.5.1. Diabetes Mellitus Market, 2021 to 2033 (USD Billion, Units)
    • 5.3.6. Others
      • 5.3.6.1. Others Market, 2021 to 2033 (USD Billion, Units)

Chapter 6. Pen and Injector Drug Delivery Devices Market: End Use Analysis

  • 6.1. End Use Movement Analysis & Market Share, 2025 & 2033
  • 6.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by End Use (USD Billion, Units)
  • 6.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
    • 6.3.1. Hospitals
      • 6.3.1.1. Hospitals Market, 2021 to 2033 (USD Billion, Units)
    • 6.3.2. Homecare Settings
      • 6.3.2.1. Homecare Settings Market, 2021 to 2033 (USD Billion, Units)
    • 6.3.3. Others
      • 6.3.3.1. Others Market, 2021 to 2033 (USD Billion, Units)

Chapter 7. Pen and Injector Drug Delivery Devices Market: Regional Estimates & Trend Analysis

  • 7.1. Pen and Injector Drug Delivery Devices Market: Regional Outlook
  • 7.2. North America
    • 7.2.1. North America Pen and Injector Drug Delivery Devices Market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.2.2. U.S.
      • 7.2.2.1. Competitive Scenario
      • 7.2.2.2. Regulatory framework
      • 7.2.2.3. Reimbursement Structure
      • 7.2.2.4. U.S. Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.2.3. Canada
      • 7.2.3.1. Competitive Scenario
      • 7.2.3.2. Regulatory framework
      • 7.2.3.3. Reimbursement Structure
      • 7.2.3.4. Canada Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.2.4. Mexico
      • 7.2.4.1. Competitive Scenario
      • 7.2.4.2. Regulatory framework
      • 7.2.4.3. Reimbursement Structure
      • 7.2.4.4. Mexico Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3. Europe
    • 7.3.1. Europe Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.2. UK
      • 7.3.2.1. Competitive Scenario
      • 7.3.2.2. Regulatory framework
      • 7.3.2.3. Reimbursement Structure
      • 7.3.2.4. UK Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.3. Germany
      • 7.3.3.1. Competitive Scenario
      • 7.3.3.2. Regulatory framework
      • 7.3.3.3. Reimbursement Structure
      • 7.3.3.4. Germany Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.4. France
      • 7.3.4.1. Competitive Scenario
      • 7.3.4.2. Regulatory framework
      • 7.3.4.3. Reimbursement Structure
      • 7.3.4.4. France Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.5. Italy
      • 7.3.5.1. Competitive Scenario
      • 7.3.5.2. Regulatory framework
      • 7.3.5.3. Reimbursement Structure
      • 7.3.5.4. Italy Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.6. Spain
      • 7.3.6.1. Competitive Scenario
      • 7.3.6.2. Regulatory framework
      • 7.3.6.3. Reimbursement Structure
      • 7.3.6.4. Spain Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.7. Norway
      • 7.3.7.1. Competitive Scenario
      • 7.3.7.2. Regulatory framework
      • 7.3.7.3. Reimbursement Structure
      • 7.3.7.4. Norway Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.8. Sweden
      • 7.3.8.1. Competitive Scenario
      • 7.3.8.2. Regulatory framework
      • 7.3.8.3. Reimbursement Structure
      • 7.3.8.4. Sweden Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.3.9. Denmark
      • 7.3.9.1. Competitive Scenario
      • 7.3.9.2. Regulatory framework
      • 7.3.9.3. Reimbursement Structure
      • 7.3.9.4. Denmark Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4. Asia
    • 7.4.1. Asia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.2. China
      • 7.4.2.1. Competitive Scenario
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Reimbursement Structure
      • 7.4.2.4. China Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.3. Japan
      • 7.4.3.1. Competitive Scenario
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Reimbursement Structure
      • 7.4.3.4. Japan Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.4. India
      • 7.4.4.1. Competitive Scenario
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Reimbursement Structure
      • 7.4.4.4. India Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.5. Thailand
      • 7.4.5.1. Competitive Scenario
      • 7.4.5.2. Regulatory framework
      • 7.4.5.3. Reimbursement Structure
      • 7.4.5.4. Thailand Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.6. South Korea
      • 7.4.6.1. Competitive Scenario
      • 7.4.6.2. Regulatory framework
      • 7.4.6.3. Reimbursement Structure
      • 7.4.6.4. South Korea Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.7. Saudi Arabia
      • 7.4.7.1. Competitive Scenario
      • 7.4.7.2. Regulatory framework
      • 7.4.7.3. Reimbursement Structure
      • 7.4.7.4. Saudi Arabia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.8. UAE
      • 7.4.8.1. Competitive Scenario
      • 7.4.8.2. Regulatory framework
      • 7.4.8.3. Reimbursement Structure
      • 7.4.8.4. UAE Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
    • 7.4.9. Kuwait
      • 7.4.9.1. Competitive Scenario
      • 7.4.9.2. Regulatory framework
      • 7.4.9.3. Reimbursement Structure
      • 7.4.9.4. Kuwait Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 8. Pen and Injector Drug Delivery Devices Market: Competitive Analysis

  • 8.1. Company Categorization
  • 8.2. Participant's Overview
  • 8.3. Financial Performance
  • 8.4. Product Offerings
  • 8.5. Company Market Position Analysis
  • 8.6. Company Market Share Analysis, 2024 (%)
  • 8.7. Strategy Mapping
    • 8.7.1. Product Launches & Approvals
    • 8.7.2. Partnerships & Collaborations
    • 8.7.3. Mergers & Acquisitions
    • 8.7.4. Expansions
    • 8.7.5. Others
  • 8.8. Company Profiles
    • 8.8.1. Novo Nordisk A/S
      • 8.8.1.1. Company Overview
      • 8.8.1.2. Financial Performance
      • 8.8.1.3. Product Benchmarking
      • 8.8.1.4. Strategic Initiatives
    • 8.8.2. Sanofi
      • 8.8.2.1. Company Overview
      • 8.8.2.2. Financial Performance
      • 8.8.2.3. Product Benchmarking
      • 8.8.2.4. Strategic Initiatives
    • 8.8.3. Eli Lilly and Company
      • 8.8.3.1. Company Overview
      • 8.8.3.2. Financial Performance
      • 8.8.3.3. Product Benchmarking
      • 8.8.3.4. Strategic Initiatives
    • 8.8.4. AstraZeneca plc
      • 8.8.4.1. Company Overview
      • 8.8.4.2. Financial Performance
      • 8.8.4.3. Product Benchmarking
      • 8.8.4.4. Strategic Initiatives
    • 8.8.5. Pfizer, Inc.
      • 8.8.5.1. Company Overview
      • 8.8.5.2. Financial Performance
      • 8.8.5.3. Product Benchmarking
      • 8.8.5.4. Strategic Initiatives
    • 8.8.6. Merck KGaA
      • 8.8.6.1. Company Overview
      • 8.8.6.2. Financial Performance
      • 8.8.6.3. Product Benchmarking
      • 8.8.6.4. Strategic Initiatives
    • 8.8.7. Teva Pharmaceuticals
      • 8.8.7.1. Company Overview
      • 8.8.7.2. Financial Performance
      • 8.8.7.3. Product Benchmarking
      • 8.8.7.4. Strategic Initiatives
    • 8.8.8. Amgen, Inc.
      • 8.8.8.1. Company Overview
      • 8.8.8.2. Financial Performance
      • 8.8.8.3. Product Benchmarking
      • 8.8.8.4. Strategic Initiatives
    • 8.8.9. Ferring Pharmaceuticals
      • 8.8.9.1. Company Overview
      • 8.8.9.2. Financial Performance
      • 8.8.9.3. Product Benchmarking
      • 8.8.9.4. Strategic Initiatives
    • 8.8.10. AbbVie, Inc.
      • 8.8.10.1. Company Overview
      • 8.8.10.2. Financial Performance
      • 8.8.10.3. Product Benchmarking
      • 8.8.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of abbreviations
  • Table 2. Estimated number of new cancer cases for all cancer types from 2025 to 2030, Incidence, Both sexes, age [0-85+]
  • Table 3. Estimated global prevalence and mortality of major chronic diseases, 2025
  • Table 4. Comparison of pen and injector drug delivery devices and conventional therapies: cost and long-term value
  • Table 5. Device preferences for top biologic classes
  • Table 6. Regional comparison of injectable drug delivery ecosystem maturity in North America
  • Table 7. Europe diabetes burden and prevalence trends (2000, 2011, 2024, and 2030 estimates)
  • Table 8. Global pen and injector drug delivery devices market revenue estimates and forecast, by product, 2021 - 2033 (USD Billion, Units)
  • Table 9. Major companies offering autoinjectors
  • Table 10. Key companies and their prefilled/smart pen product offerings
  • Table 11. Global pen and injector drug delivery devices market revenue estimates and forecast, by drug type, 2021 - 2033 (USD Billion, Units)
  • Table 12. Global injectors market, by drug type, 2021- 2033 (USD Billion, Units)
  • Table 13. Global pen market, by drug type, 2021- 2033 (USD Billion, Units)
  • Table 14. Key GLP-1 agonist pen products
  • Table 15. Global pen and injector drug delivery devices market revenue estimates and forecast, by therapeutic use, 2021 - 2033 (USD Billion, Units)
  • Table 16. Global ranking of countries by obesity prevalence (%)
  • Table 17. Global pen and injector drug delivery devices market revenue estimates and forecast, by end use, 2021 - 2033 (USD Billion, Units)
  • Table 18. Canada regulatory procedure for medical devices
  • Table 19. Cancer statistics and rankings for France, 2022

List of Figures

  • Figure 1. Pen and injector drug delivery devices market segmentation
  • Figure 2. Pen and injector drug delivery devices market segmentation
  • Figure 3. Market research process
  • Figure 4. Information procurement
  • Figure 5. Primary research pattern
  • Figure 6. Market research approaches
  • Figure 7. Value chain-based size & forecasting
  • Figure 8. Market formulation & validation
  • Figure 9. Pen and injector drug delivery devices market revenue
  • Figure 10. Volume price analysis
  • Figure 11. CDMO pen and injector drug delivery devices market revenue
  • Figure 12. Market snapshot (regional)
  • Figure 13. Segment snapshot (product)
  • Figure 14. Segment snapshot (drug type)
  • Figure 15. Segment snapshot (therapeutic use)
  • Figure 16. Segment snapshot (end use)
  • Figure 17. Market concentration
  • Figure 18. Pen and injector drug delivery devices market dynamics
  • Figure 19. Pen and injector drug delivery devices market: PORTER's analysis
  • Figure 20. Pen and injector drug delivery devices market: PESTEL analysis
  • Figure 21. Estimated number of cancer cases in Europe, by Country, 2022 Vs. 2025 Vs 2030
  • Figure 22. Pen and injector drug delivery devices market, by product: Key takeaways
  • Figure 23. Pen and injector drug delivery devices market, by product: Market share, 2025 & 2033
  • Figure 24. Injectors market, 2021 - 2033 (USD Billion, Units)
  • Figure 25. Pens market, 2021 - 2033 (USD Billion, Units)
  • Figure 26. Pen and injector drug delivery devices market, by drug type: Key takeaways
  • Figure 27. Pen and injector drug delivery devices market, by drug type: Market share, 2025 & 2033
  • Figure 28. GLP-1 agonists market, 2021 - 2033 (USD Billion, Units)
  • Figure 29. Hormone therapies market, 2021 - 2033 (USD Billion, Units)
  • Figure 30. Biologics market, 2021 - 2033 (USD Billion, Units)
  • Figure 31. Others market, 2021 - 2033 (USD Billion, Units)
  • Figure 32. GLP-1 agonists market, 2021 - 2033 (USD Billion, Units)
  • Figure 33. Insulin market, 2021 - 2033 (USD Billion, Units)
  • Figure 34. Others market, 2021 - 2033 (USD Billion, Units)
  • Figure 35. Pen and injector drug delivery devices market, by therapeutic use: Key takeaways
  • Figure 36. Pen and injector drug delivery devices market, by therapeutic use: Market share, 2025 & 2033
  • Figure 37. Autoimmune disorders market, 2021 - 2033 (USD Billion, Units)
  • Figure 38. Hormonal disorders market, 2021 - 2033 (USD Billion, Units)
  • Figure 39. Oncology market, 2021 - 2033 (USD Billion, Units)
  • Figure 40. Obesity market, 2021 - 2033 (USD Billion, Units)
  • Figure 41. Diabetes mellitus market, 2021 - 2033 (USD Billion, Units)
  • Figure 42. Others market, 2021 - 2033 (USD Billion, Units)
  • Figure 43. Pen and injector drug delivery devices market, by end use: Key takeaways
  • Figure 44. Pen and injector drug delivery devices market, by end use: Market share, 2025 & 2033
  • Figure 45. Hospitals market, 2021 - 2033 (USD Billion, Units)
  • Figure 46. Homecare settings market, 2021 - 2033 (USD Billion, Units)
  • Figure 47. Others market, 2021 - 2033 (USD Billion, Units)
  • Figure 48. Pen and injector drug delivery devices market revenue, by region, 2025 & 2033 (USD Billion, Units)
  • Figure 49. Regional marketplace: Key takeaways
  • Figure 50. Regional marketplace: Key takeaways
  • Figure 51. North America pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 52. Estimated number of new cancer cases, by State -- 2025
  • Figure 53. Diagnosed diabetes - total, adults aged 18+ years, age-adjusted percentage (2023)
  • Figure 54. Reimbursement procurement process
  • Figure 55. U.S. pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 56. Diabetes mellitus (types combined), excluding gestational diabetes, age-standardized incidence rate, per 100,000, age 1 year old and older, Canada
  • Figure 57. Canada pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 58. Mexico pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 59. Europe pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 60. UK pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 61. Germany pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 62. France pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 63. Italy pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 64. Spain pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 65. Sweden pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 66. Norway pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 67. Denmark pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 68. Asia pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 69. China pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 70. Japan pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 71. India pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 72. Thailand pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 73. South Korea pen and injector drug delivery market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 74. Saudi Arabia pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 75. UAE pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 76. Kuwait pen and injector drug delivery devices market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • Figure 77. Key company categorization
  • Figure 78. Company market share analysis, 2025
  • Figure 79. Strategy mapping